Dixon Hubard Feinour & Brown’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$717K	Hold	8,986	–	–	0.09%	171
2022 Q1	$945K	Sell	8,986 -5,132	-36%	-$500K	0.09%	167
2021 Q4	$1.52M	Buy	14,118 +313	+2%	+$34.1K	0.15%	134
2021 Q3	$1.51M	Hold	13,805	–	–	0.32%	64
2021 Q2	$1.29M	Sell	13,805 -22,220	-62%	-$2.04M	0.27%	77
2021 Q1	$2.99M	Buy	36,025 +13,250	+58%	+$1.12M	0.37%	64
2020 Q4	$1.77M	Hold	22,775	–	–	0.45%	45
2020 Q3	$1.77M	Hold	22,775	–	–	0.45%	45
2020 Q2	$1.35M	Hold	22,775	–	–	0.35%	61
2020 Q1	$675K	Hold	22,775	–	–	0.23%	77
2019 Q4	$824K	Hold	22,775	–	–	0.21%	88
2019 Q3	$620K	Buy	22,775 +250	+1%	+$6.46K	0.17%	100
2019 Q2	$542K	Buy	22,525 +5,925	+36%	+$150K	0.15%	106
2019 Q1	$439K	Buy	+16,600	New	+$393K	0.13%	111

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Dixon Hubard Feinour & Brown's HZNP Position: Q2 2022 in Review

Dixon Hubard Feinour & Brown held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q2 2022 at 8,986 shares worth $717K. The position accounts for 0.09% of the portfolio, ranked #171.

Dixon Hubard Feinour & Brown first reported a position in HZNP in Q1 2019 and has held it in 14 quarters since. The position peaked at $2.99M in Q1 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Dixon Hubard Feinour & Brown held 8,986 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $717K as of Q2 2022.
Dixon Hubard Feinour & Brown left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q2 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.09% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #171 holding.
Dixon Hubard Feinour & Brown first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and has held it in 14 quarters since.
Dixon Hubard Feinour & Brown's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.99M in Q1 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.